Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 249-260

  Flanagan, James M ^a,c   Funes, Juan M ^a   Henderson, Stephen ^a   Wild, Laurence ^a   Carey, Nessa ^b   Boshoff, Chris ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CellCentric   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DEAMINASE; ATOVAQUONE PLUS PROGUANIL; CELECOXIB; CLOMIPRAMINE; DOXORUBICIN; FLUOROURACIL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMOTRIGINE; METHOTREXATE; PEMETREXED; PHOSPHATIDATE PHOSPHATASE; PRAVASTATIN; PROGUANIL; PROSTAGLANDIN; PROTEIN P53; PYRIMETHAMINE; RIBONUCLEASE; ROFECOXIB; SMALL INTERFERING RNA; TRIMETREXATE; VALDECOXIB;

ADULT; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL CULTURE; CARCINOMA; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL TRANSFORMATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG TARGETING; ENZYME ANALYSIS; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; TRANSCRIPTION REGULATION; TUMOR GENE; UPREGULATION;

ADENOSINE DEAMINASE; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; GENOMICS; HUMANS; NEOPLASMS; PHOSPHATIDATE PHOSPHATASE; RIBONUCLEASE H; STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 58149492132     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0636     Document Type: Article

References (43)

1. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-16.
2. Lindsay MA. Target discovery. Nat Rev 2003;2:831-8.
3. Hopkins AL, Groom CR. The druggable genome. Nat Rev 2002;1:727-30.
4. Russ AP, Lampel S. The druggable genome: an update. Drug Discov Today 2005;10:1607-10.
5. Mayburd AL, Golovchikova I, Mulshine JL. Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets. Bioinformatics 2008;24:389-95.
6. Okuyama M, Laman H, Kingsbury SR, et al. Small-molecule mimics of an α-helix for efficient transport of proteins into cells. Nat Methods 2007;4:153-9.
7. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther 2006;13:464-77.
8. Silva JM, Marran K, Parker JS, et al. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 2008;319:617-20.
9. Schlabach MR, Luo J, Solimini NL, et al. Cancer proliferation gene discovery through functional genomics. Science 2008;319:620-4.
10. Solimini NL, Luo J, Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007;130:986-8.
11. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. Opinion. The origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 2005;5:899-904.
12. Alison MR, Murphy G, Leedham S. Stem cells and cancer: a deadly mix. Cell Tissue Res 2008;331:109-24.
13. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8.
14. Funes JM, Quintero M, Henderson S, et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A 2007;104:6223-8.
15. Henderson SR, Guiliano D, Presneau N, et al. A molecular map of mesenchymal tumors. Genome Biol 2005;6:R76.
16. Suzuki R, Shimodaira H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 2006;22:1540-2.
17. Zeller KI, Zhao X, Lee CW, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A 2006;103:17834-9.
18. Bataille F, Rogler G, Modes K, et al. Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/β-catenin. Lab Invest 2005;85:124-36.
19. Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer 2007;43:415-32.
20. Arolas JL, Vendrell J, Aviles FX, Fricker LD. Metallocarboxypeptidases: emerging drug targets in biomedicine. Curr Pharm Des 2007;13:349-66.
21. Schweiger A, Christensen IJ, Nielsen HJ, Sorensen S, Brunner N, Kos J. Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer. Int J Biol Markers 2004;19:289-94.
22. Frank P, Braunshofer-Reiter C, Wintersberger U, Grimm R, Busen W. Cloning of the cDNA encoding the large subunit of human RNase HI, a homologue of the prokaryotic RNase HII. Proc Natl Acad Sci U S A 1998;95:12872-7.
23. Brindley DN. Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J Cell Biochem 2004;92:900-12.
24. Tanyi JL, Morris AJ, Wolf JK, et al. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res 2003;63:1073-82.
25. Morris KE, Schang LM, Brindley DN. Lipid phosphate phosphatase-2 activity regulates S-phase entry of the cell cycle in Rat2 fibroblasts. J Biol Chem 2006;281:9297-306.
26. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-3.
27. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclooxygenase 2: a new class of anticancer agents? Lancet Oncol 2003;4:605-15.
28. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
29. Fasig JH, Dupont WD, Olson SJ, Lafleur BJ, Cates JM. Steroid hormone receptor and COX-2 expression in chordoma. Am J Clin Pathol 2007;128:375-81.
30. Endo M, Matsumura T, Yamaguchi T, et al. Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas. Hum Pathol 2006;37:471-6.
31. Huennekens FM. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul 1994;34:397-419.
32. Pirard B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov Today 2007;12:640-6.
33. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008;9:162-76.
34. Buchanan FG, McReynolds M, Couvillon A, et al. Requirement of phospholipase D1 activity in H-RasV12-induced transformation. Proc Natl Acad Sci U S A 2005;102:1638-42.
35. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12.
36. Crow YJ, Leitch A, Hayward BE, et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat Genet 2006;38:910-6.
37. Qiu J, Qian Y, Frank P, Wintersberger U, Shen B. Saccharomyces cerevisiae RNase H(35) functions in RNA primer removal during lagging-strand DNA synthesis, most efficiently in cooperation with Rad27 nuclease. Mol Cell Biol 1999;19:8361-71.
38. Chapman EJ, Carrington JC. Specialization and evolution of endogenous small RNA pathways. Nat Rev Genet 2007;8:884-96.
39. Yin H, Lin H. An epigenetic activation role of Piwi and a Piwi-associated piRNA in Drosophila melanogaster. Nature 2007;450:304-8.
40. Schoft VK, Schopoff S, Jantsch MF. Regulation of glutamate receptor B pre-mRNA splicing by RNA editing. Nucleic Acids Res 2007;35:3723-32.
41. Maas S, Patt S, Schrey M, Rich A. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci U S A 2001;98:14687-92.
42. Paz N, Levanon EY, Amariglio N, et al. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res 2007;17:1586-95.
43. Benson JD, Chen YN, Cornell-Kennon SA, et al. Validating cancer drug targets. Nature 2006;441:451-6.